Monday, April 05, 2010
NHGRI Names New Chief of Genome Technology Branch, April 5, 2010 News Release - National Institutes of Health (NIH) U.S.
"Dr. Brody has headed GTB's Molecular Pathogenesis Section, investigating genetic variants that lead to changes in normal metabolic pathways to cause cancer and birth defects. He has made key discoveries regarding the genetics of breast cancer and neural tube defects. For example, the Brody laboratory was among the first to report that women who carry mutations in the BRCA1 or BRCA2 genes are at a higher risk of developing both breast cancer and ovarian cancer compared to women without such mutations. In addition, his group was the first to report that the frequency of specific BRCA1 and BRCA2 gene mutations are elevated in the Jewish population. In collaboration with scientists at Howard University, Washington, D.C., he described a series of mutations and rare variants in BRCA1 carried by some African-American women with breast and ovarian cancer."
uTube - Bradley J. Monk, MD, University of California Irvine talks about early stage ovarian cancer including clear cell SGO
Note: the title on this video is wrong
utube: Thomas J. Herzog, MD, Columbia University College of Physicians and Surgeons talks about liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced malignancy SGO
Thomas J. Herzog, MD, Columbia University College of Physicians and Surgeons talks about liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced malignancy.
Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas
OBJECTIVE: To evaluate drug resistance after exposure to neoadjuvant chemotherapy and to postoperative chemotherapy in epithelial ovarian, fallopian, and primary peritoneal carcinomas.
Reminder: A patient's perspective on ovarian cancer as a chronic disease—Devaluing a survivor's challenge Caridad Vera-Garcia
Note: Cary is now with us 'in spirit'
Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?
Note: the authors' opinions confirm ovarian cancer as a chronic disease
full free access: COMMENTARY Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
"Inhibiting angiogenesis is an effective approach to cancer therapy, but it has been associated with cardiovascular toxic effects. At times, adverse events such as hypertension and heart failure have led to treatment cessation and even life-threatening consequences. Cancer patients have often been excluded from studies of cardiovascular disease, and patients with clinically significant cardiovascular disease have been excluded from studies of new cancer therapies. Consequently, the capacity for determining the incidence or prevalence of cardiovascular toxic effects of anticancer agents and to determine their optimal management has been limited. Oncologists and cardiovascular medicine specialists have increasingly recognized that the prevention and management of these toxic effects is important for these potentially life-sustaining anticancer agents to benefit the greatest possible number of patients."
Box 1. Summary recommendations
HE4: a new potential early biomarker for the recurrent ovarian cancer
"The follow-up study showed an increase of HE4 5-8 months before CA125 increment in five of the eight patients, this early expression being strictly associated to a relapse of the disease. In conclusion, this study showed that HE4, compared to CA125, potentially is a better marker for the diagnosis of OC and could be an important early indicator of the recurrence of the disease."
Epidemiologic evidence on coffee and cancer
Nutr Cancer. 2010 Apr;62(3):271-83.
Epidemiologic evidence on coffee and cancer.
Arab L.
David Geffen School of Medicine, University of California, Los Angeles, USA.
Coffee consumption is a major and frequent dietary exposure in diverse cultures around the globe whose safety has been questioned. A substantial body of epidemiologic evidence, consisting of over 500 papers relating the consumption of coffee to cancer of various sites, has accumulated to date. Numerous individual, site-specific meta analyses have been undertaken at various times. However, there is no comprehensive, up-to-date overview of the entirety of the knowledge base. To address this need, this review summarized the findings of the meta analyses and recent papers on site-specific human cancers among coffee consumers. For hepatocellular and endometrial cancers, there appears to be a strong and consistent protective association; for colorectal cancer, the direction of association is borderline protective. There appears to be no association with breast, pancreatic, kidney, ovarian, prostate, or gastric cancer. Risk of bladder cancer appears to be associated with heavy coffee consumption in some populations and among men. The associations with childhood leukemia and mother's consumption of coffee were ambiguous-with some suggestion of risk at high levels of daily consumption.
PMID: 20358464 [PubMed - in process]
Clinical Trials Canada - preformated search
Search - preformated - Ovarian / Fallopian Tube / Peritoneal = 58 clinical trials
Note:
1) results are not necessarily specific to Ovarian/FT/P cancer but include differing tumor types (cancers) e.g.phase 1;
2) should be cross referenced to http://www.clinicaltrials.gov for potential duplications/excluded/not included
DOD (patient safety) Defense.gov News Article: Officials Step Up Patient Safety Efforts
“It’s OK to make and identify an error,” he added, “It’s not OK to cover up an error.”
Study: Patient Safety Incidents at U.S. Hospitals Show No Decline, Cost $9 Billion - financial news
The following are the 15 patient safety indicators studied:
Complications of anesthesia
Death in low mortality Diagnostic Related Groupings (DRGs)
Decubitus ulcer (bed sores)
Death among surgical inpatients with serious treatable
complications
Iatrogenic pneumothorax
Selected infections due to medical care
Post-operative hip fracture
Post-operative hemorrhage or hematoma
Post-operative physiologic and metabolic derangements
Post-operative respiratory failure
Post-operative pulmonary embolism or deep vein thrombosis
Post-operative sepsis
Post-operative abdominal wound dehiscence
Accidental puncture or laceration
Transfusion reaction
Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering - media article
"HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes. This new service is based on an 80-gene signature that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancer tumors...."
free full access: A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
for full free access click on 'pdf'
Search of: ovarian cancer | Open Studies | received from 03/01/2010 to 04/05/2010 - List Results - ClinicalTrials.gov
12 new clinical trials listed - search terms: ovarian cancer | Open Studies | received from 03/01/2010 to 04/05/2010
Rank Status Study
1 Not yet recruiting Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
2 Recruiting Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Ovarian Cancer and Inoperable Malignant Bowel Obstruction
Conditions: Ovarian Cancer; Bowel Obstruction
3 Recruiting Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
4 Not yet recruiting Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Condition: Ovarian Cancer
5 Recruiting MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma
6 Not yet recruiting First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer
Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
7 Recruiting Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Condition: Ovarian Cancer
8 Not yet recruiting Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
9 Recruiting Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
10 Recruiting A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
Conditions: Ovarian Neoplasms; Breast Neoplasms; Prostatic Neoplasms
Intervention: Biological: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
11 Recruiting Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Conditions: Fallopian Tube Cancer; Ovarian Sarcoma; Ovarian Stromal Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Uterine Sarcoma; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Uterine Sarcoma; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IV Endometrial Carcinoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Uterine Sarcoma; Stage IV Vulvar Cancer; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer
12 Recruiting Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours
ACOR
Subscribe to:
Posts
(
Atom
)
Posts
